Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Parenteral nutrition support for patients with advanced pancreatic cancer – interim results from the sub-project „PaNut“ of the Pancreatic Cancer Registry (TPK).

Hegewisch-Becker, S., Wolf, T., Reiser, M., Scheiner-Sparna, R., Hamm, D., Marschner, N., 2016.

Oncol Res Treat 39 (suppl3)(P869), 261. doi:10.1159/000449050

Abstract

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2016
Patient-reported outcomes of patients with advanced or metastatic pancreatic cancer in German outpatient centres – first data from the sub-project PanLife of the clinical Pancreatic Cancer Registry (TPK).

Hegewisch-Becker, S., Wolf, T., Aldaoud, A., Scheiner-Sparna, R., Hamm, D., Marschner, N., 2016.

Oncol Res Treat 39 (suppl3)(V1026), 318 doi:10.1159/000449050

Abstract

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2016
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W.E., Marschner, N., Jänicke, M., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Sebastian, M., Thomas, M., 2016.

Oncol Res Treat 39 (suppl3)(P295), 90. doi:10.1159/000449050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2016
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Wolff, T., Schulz, H., Sandner, R., Reichert, D., Hurtz, H.-J., Müller, J., Grebhardt, S., 2016.

Oncol Res Treat, DGHO-Jahrestagung (Leipzig) 39 (suppl3)(P950), 292. doi:10.1159/000449050

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Kurbacher, C.M., Trarbach, T., Salat, C., Rezai, M., Lorenz, A., Niemeier, B., 2016.

Oncol Res Treat 39 (suppl3)(P952), 293. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016
First interim analysis of OTILIA, a large German non-interventional study evaluating bevacizumab-containing therapy in patients with ovarian cancer.

Mustea, A., Mahner, S., Oskay-Oezcelik, G., Wimberger, P., Jungberg, S., Reichert, D., Forstbauer, H., Keller, M., Richter, R., Frank, M., Klawitter, S., Kiewitz, C., Müller, M., Sehouli, J., 2015.

ESMO Annual Meeting (Vienna)

Indikation: Ovarialkarzinom, Ovarian Cancer / Veranstaltung: ESMO / Journal: -
OTILIA
2015
Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany.

Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Meinerz, Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Meinerz, W., 2015.

Annual Meeting ESGO (Society of Gynaecological Oncology) (0919).

Indikation: Other, Ovarialkarzinom, Ovarian Cancer, Sonstige / Veranstaltung: ESGO / Journal: -
OTILIA
2015
Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015.

Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PIAZA
2015
Do we miss changes in Quality of Life? Data from the LuLife project in patients with non-small cell lung cancer in Germany.

von Verschuer, U., Sandner, R., Däßler, K.-U., Tessen, H.W., Münz, M., Spring, L., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V45), 13. doi:10.1159/000439070

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2015
Prevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.

Tesch, H., Ulshöfer, T., Vehling-Kaiser, U., Ottillinger, B., Bulenda, D., Turner, M., 2015.

Oncol Res Treat 38, 146–152. doi:10.1159/000381318

Abstract

Indikation: Supportive Therapy, Supportivtherapie / Veranstaltung: - / Journal: Oncology Research and Treatment
HEXAFIL
2015